Adaptyv Biosystems Analysis: $108K Raised
What is Adaptyv Biosystems?
Adaptyv Bio runs a cloud laboratory for protein designers and AI teams working on new protein sequences. The company reports experimental data delivery in as little as 21 days and sells protein validation through assay-based services. Its platform centers on binding, expression, and thermostability testing for lab-in-the-loop protein design.
Location
Lausanne, Switzerland
Employees
11-50
Founded
2021
Revenue
$2.6M
Business Model
Revenue generated through designed proteins and automated workcell services.
Product Features & Capabilities
- AI-driven protein design, high-quality experimental data generation for designed proteins, cell-free synthetic biology for protein synthesis, automated workcells for profiling protein functions, integration of AI in the protein engineering cycle.
How much Adaptyv Biosystems raised
1 - $108K
July 1, 2021Lead Investor: Foundation for Innovation and Technology (FIT)
Who are the founders of Adaptyv Biosystems
JE
Julian Englert
Founder
DN
Daniel Nakhaee-Zadeh Gutierrez
Founder, COO
Investors
- Y Combinator
- Acequia Capital
- Venture Kick
- Foundation for Innovation and Technology (FIT)
- FAST — by GETTYLAB
Competitors Overview
Adaptyv Biosystems operates in the protein engineering and AI biotechnology market, where it faces competition from several notable companies:
-
Generate Biomedicines: This company utilizes machine learning to generate protein therapeutics. Their advantage lies in their ability to rapidly design and optimize proteins for therapeutic use, leveraging a robust AI platform.
-
Absci Corporation: Absci focuses on designing novel antibodies using AI technology. Their unique approach combines synthetic biology with AI to create high-quality therapeutic proteins, which can be a significant advantage in the competitive landscape.
-
Nabla Bio: An AI-first platform for antibody therapeutics, Nabla Bio emphasizes the integration of AI in the drug discovery process, which allows for faster and more efficient development of new therapies.
-
Antiverse: This company specializes in in silico models for antibody discovery, providing a computational approach that can significantly reduce the time and cost associated with traditional methods.
-
Exscientia: Known for its AI drug discovery platform, Exscientia focuses on precision medicine, which allows for tailored therapeutic solutions based on individual patient data.
-
Insilico Medicine: This company is involved in AI-driven drug discovery and biomarker development, offering a comprehensive approach that combines various AI techniques to enhance drug development processes.
-
Recursion Pharmaceuticals: They integrate biology and AI for drug discovery, focusing on using AI to analyze biological data and identify potential therapeutic targets.
These competitors highlight a trend towards leveraging AI in protein design and drug discovery, with each company offering unique advantages such as speed, efficiency, and tailored solutions in their respective approaches.
Market Focus
Adaptyv Biosystems primarily focuses on the biotechnology industry, specifically in the area of protein engineering and artificial intelligence applications for advancements in medicine, manufacturing, computation, and power generation.
See something that needs updating? Suggest edits to this profile.